Vorapaxar – thrombin receptor antagonist

Vorapaxar – thrombin receptor antagonist

Vorapaxar – thrombin receptor antagonist: Vorapaxar is an oral protease-activated–receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Pierluigi Tricoci, Zhen Huang, Claes Held, David J Moliterno, Paul W Armstrong, Frans Van de Werf, Harvey D White, Philip E Aylward, Lars Wallentin, Edmond Chen, Yuliya Lokhnygina, Jinglan Pei, Sergio Leonardi, Tyrus L Rorick, Ann M Kilian, Lisa H K Jennings, Giuseppe Ambrosio, Christoph Bode, Angel Cequier, Jan H Cornel, Rafael Diaz, Aycan Erkan, Kurt Huber, Michael P Hudson, Lixin Jiang, J Wouter Jukema, Basil S Lewis, A Michael Lincoff, Gilles Montalescot, José Carlos Nicolau, Hisao Ogawa, Matthias Pfisterer, Juan Carlos Prieto, Witold Ruzyllo, Peter R Sinnaeve, Robert F Storey, Marco Valgimigli, David J Whellan, Petr Widimsky, John Strony, Robert A Harrington and Kenneth W Mahaffey, the TRACER Investigators [1] evaluated the role of vorapaxar in acute coronary syndrome, in a double-blind, randomized placebo controlled trial involving about thirteen thousand patients. They concluded that adding vorapaxar to standard therapy did not significantly reduce the primary composite endpoint, but increased the risk of major bleeding including intracranial hemorrhage.

Reference

1. Pierluigi Tricoci, Zhen Huang, Claes Held, David J Moliterno, Paul W Armstrong, Frans Van de Werf, Harvey D White, Philip E Aylward, Lars Wallentin, Edmond Chen, Yuliya Lokhnygina, Jinglan Pei, Sergio Leonardi, Tyrus L Rorick, Ann M Kilian, Lisa H K Jennings, Giuseppe Ambrosio, Christoph Bode, Angel Cequier, Jan H Cornel, Rafael Diaz, Aycan Erkan, Kurt Huber, Michael P Hudson, Lixin Jiang, J Wouter Jukema, Basil S Lewis, A Michael Lincoff, Gilles Montalescot, José Carlos Nicolau, Hisao Ogawa, Matthias Pfisterer, Juan Carlos Prieto, Witold Ruzyllo, Peter R Sinnaeve, Robert F Storey, Marco Valgimigli, David J Whellan, Petr Widimsky, John Strony, Robert A Harrington, Kenneth W Mahaffey, TRACER Investigators. Thrombin-receptor Antagonist Vorapaxar in Acute Coronary Syndromes. N Engl J Med. 2012 Jan 5;366(1):20-33.